Video Shorts

The “Million-Dollar Question”: Can Romiplostim Improve Outcomes by Maintaining Chemo Dose Intensity?

An Analysis of Urinary Proteomics in Bladder Cancer

Investigating TTFields in Newly Diagnosed Glioblastoma

How Is AI Changing GU Cancer Surgery?

Inside the Science Behind Personalized Vaccine Development for Pancreatic Cancer

Previewing Updated Data From ASCENT-03 and ASCENT-04 Upcoming at ASCO 2026

Raising Bladder Cancer Awareness

Previewing ASCO 2026: SUCCESSOR-2 Trial in R/R Multiple Myeloma

OncLive News Roundup for the Week of 5/17

Previewing Key Breast Cancer Abstracts to Watch at ASCO 2026

Breaking Down Mogamulizumab-Associated Rashes in CTCL

Previewing ASCO 2026: SENTRY, RALLY-MF Trials Represent Key MPN Abstracts

Pancreatic Cancer Vaccines Aim to Bolster Long-Term Disease Control

Previewing ASCO 2026: Myeloma Abstracts to Watch

Live From AUA 2026: Interviewees Share Notable Data in GU Cancers

Previewing ASCO 2026: Key MPN Presentations to Watch

What Are Experts Doing in DC Besides Attending the 2026 AUA Annual Meeting?

Discussing Findings From a Post Hoc Analysis of DAROL in Prostate Cancer

Why There’s Still No Clear Treatment Roadmap for Treatment Sequencing in NETs

Unpacking the PSA End Points of PSMAddition in Prostate Cancer

OncLive News Roundup for the Week of 5/10

What Are the Biggest Unanswered Questions That Will Be Addressed at AUA 2026?

Follow-Up After Focal Cryo-Ablation in Intermediate Favorable Risk Prostate Cancer

Highlighting the Role of Real-World Studies in Bladder Cancer

Implementing a Multidisciplinary Quality Initiative in Prostate Cancer

Real-World Experience With BCG Retreatment After BCG Failure in NMIBC

Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Prostate Cancer

Examining the Landscape of Biomarkers in RCC

Sequencing T-Cell–Redirecting Therapies in Multiple Myeloma

Breaking Down the FDA Approval of Nivolumab AVD for Untreated Classical Hodgkin Lymphoma